EMEA-001971-PIP03-18-M02
Key facts
| Invented name |
Vitrakvi
|
| Active substance |
Larotrectinib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0289/2022
|
| PIP number |
EMEA-001971-PIP03-18-M02
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of malignant neoplasms of the central nervous system
|
| Route(s) of administration |
|
| Contact for public enquiries |
Bayer AG
Tel. +49 3046815333 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|